<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01737697</url>
  </required_header>
  <id_info>
    <org_study_id>ZS-003</org_study_id>
    <nct_id>NCT01737697</nct_id>
  </id_info>
  <brief_title>Safety &amp; Efficacy of Zirconium Silicate in Mild to Moderate Hyperkalemia</brief_title>
  <official_title>Multicenter, Two-phase, Multi-dose, Prospective, Randomized, Double-blind, Placebo-Controlled Study of Safety and Efficacy of Microporous, Fractionated, Protonated Zirconium Silicate in Mild to Moderate Hyperkalemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ZS Pharma, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ZS Pharma, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Acute Phase: It is hypothesized that ZS (zirconium silicate) is more effective than placebo
      control (alternative hypothesis) in lowering S-K levels in subjects with S-K between 5.0 -
      6.5 mmol/l versus no difference between ZS and placebo control (null hypothesis).

      Subacute Phase (randomized withdrawal): It is hypothesized that ZS once daily is more
      effective than placebo control (alternative hypotheses) in maintaining normokalemic levels
      (3.5 - 4.9 mmol/l) among subjects completing the Acute Phase versus no difference between
      each ZS dose and respective placebo controls (null hypotheses).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A total of 750 subjects with mild to moderate hyperkalemia (i- STAT potassium levels between
      5.0-6.5 mmol/l, inclusive) will be enrolled in the study where they, in a double-blind
      fashion, will be randomized 1:1:1:1:1 to receive one of four (4) doses of ZS (1.25g, 2.5g,
      5g, and 10g) or placebo control, administered 3 times daily (tid) with meals for the initial
      48 hours (Acute Phase), followed by a Subacute Phase (randomized withdrawal) during which
      patients treated with active doses in the Acute Phase, who achieve normokalemia (i-STAT
      potassium values 3.5 to 4.9 mmol/l, inclusive) will be randomized to 12 days of subacute,
      once a day (qd) dosing. There will be a one-time randomization to assign the Acute Phase
      treatment and the Subacute Phase treatment. The Subacute Phase will include subjects who
      became normokalemic on active drug and those who became normokalemic on placebo. The former
      will be randomized in a 1:1 ratio between the same dose of ZS they received during the acute
      phase but only administered once a day (qd) or placebo, qd. Subjects on placebo during the
      Acute Phase who are normokalemic in the morning of Study Day 3, will be randomized to receive
      either 1.25 or 2.5 g ZS, qd as Subacute Phase treatment.

      Safety and tolerability will be assessed on an ongoing basis by an Independent Data Safety
      Monitoring Board (DSMB). Each active dose group will consist of 150 patients per treatment
      group including the placebo control group for a total of 750 patients; the 1:1:1:1:1
      allocation helps to optimize the multiple active dose comparisons to the respective placebo
      controls for the Subacute Phase.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Actual">November 2013</completion_date>
  <primary_completion_date type="Actual">October 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in serum potassium levels from baseline after administration of zirconium silicate three times a day.</measure>
    <time_frame>first 48 hours</time_frame>
    <description>To perform a controlled evaluation of the safety and efficacy of four (4) different doses of ZS administered 3 times daily for 48 hours in the Acute Phase for patients with mild to moderate hyperkalemia (potassium level between 5.0-6.5 mmol/l as determined by i-STAT) at baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in serum potassium levels from baseline after administration of zirconium silicate once a day for patients who first completed 48 hours of dosing tid.</measure>
    <time_frame>additional 12 days</time_frame>
    <description>To perform a controlled evaluation of the safety and efficacy of four different doses of ZS administered once daily for 12 additional days in a subsequent Subacute Phase for patients completing the Acute Phase and achieving potassium levels within the normal range (3.5 - 4.9 mmol/l, as determined by i-STAT).</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in serum sodium, magnesium, calcium and blood urea nitrogen (BUN) from baseline after administration of zirconium silicate three times a day.</measure>
    <time_frame>first 48 hours</time_frame>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">750</enrollment>
  <condition>Hyperkalemia</condition>
  <arm_group>
    <arm_group_label>Zirconium silicate (acute phase)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Randomized oral doses (1.25g, 2.5g, 5g, and 10g) of microporous, fractionated, protonated zirconium silicate administered 3 times (tid) daily with meals for 48 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo ( silicified microcrystalline cellulose) randomized to mimic doses of experimental drug administered 3 times (tid) daily with meals.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Zirconium silicate (subacute phase)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Randomized oral doses (1.25g, 2.5g, 5g, and 10g) of microporous, fractionated, protonated zirconium silicate administered once a day prior to the morning meal for 12 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (subacute phase)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (silicified microcrystalline cellulose) randomized to mimic doses of experimental drug administered once a day (qd) prior to the morning meal for 12 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zirconium silicate (acute phase)</intervention_name>
    <description>Randomized oral doses (1.25g, 2.5g, 5g, and 10g) of microporous, fractionated, protonated zirconium silicate administered 3 times (tid) daily with meals for 48 hours.</description>
    <arm_group_label>Zirconium silicate (acute phase)</arm_group_label>
    <other_name>ZS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zirconium silicate (subacute phase)</intervention_name>
    <description>Randomized oral doses (1.25g, 2.5g, 5g, and 10g) of microporous, fractionated, protonated zirconium silicate administered once a day prior to the morning meal for 12 days.</description>
    <arm_group_label>Zirconium silicate (subacute phase)</arm_group_label>
    <other_name>ZS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Randomized to mimic doses of experimental drug administered 3 times (tid) daily with meals for 48 hours during the acute phase.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Silicified microcrystalline cellulose</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo ( subacute phase)</intervention_name>
    <description>Randomized to mimic doses of experimental drug administered once a day prior to the morning meal for 12 days during the subacute phase.</description>
    <arm_group_label>Placebo (subacute phase)</arm_group_label>
    <other_name>Silicified microcrystalline cellulose</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provision of written informed consent.

          -  Over 18 years of age.

          -  Mean i-STAT potassium values between 5.0 - 6.5 mmol/l inclusive, at screening (Study
             Day 0).

          -  Ability to have repeated blood draws or effective venous catheterization.

          -  Women of childbearing potential must be practicing a highly effective method of birth
             control.

        Exclusion Criteria:

          -  Pseudohyperkalemia signs and symptoms, such as excessive fist clinching hemolyzed
             blood specimen, severe leukocytosis or thrombocytosis.

          -  Subjects treated with lactulose, xifaxan or other nonabsorbed antibiotics for
             hyperammonemia within the last 7 days.

          -  Subjects treated with resins (such as Sevelamer acetate or Sodium polystyrene
             sulfonate [SPS; e.g. KayexalateÂ®]), calcium acetate, calcium carbonate, or lanthanum
             carbonate, within the last 7 days.

          -  Subjects with a life expectancy of less than 3 months.

          -  Subjects who are HIV positive.

          -  Subjects who are severely physically or mentally incapacitated and who in the opinion
             of investigator are unable to perform the subjects' tasks associated with the
             protocol.

          -  Women who are pregnant, lactating, or planning to become pregnant.

          -  Subjects with Ketoacidosis/Acidemia.

          -  Presence of any condition which, in the opinion of the investigator, places the
             subject at undue risk or potentially jeopardizes the quality of the data to be
             generated.

          -  Known hypersensitivity or previous anaphylaxis to ZS or to components thereof.

          -  Previous treatment with ZS

          -  Treatment with a drug or device within the last 30 days that has not received
             regulatory approval at the time of study entry.

          -  Subjects with cardiac arrhythmias that require immediate treatment.

          -  Insulin-dependent diabetes mellitus

          -  Subjects on dialysis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Henrik Rasmussen, MD</last_name>
    <role>Study Chair</role>
    <affiliation>ZS Pharma, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pinnacle Research Group</name>
      <address>
        <city>Anniston</city>
        <state>Alabama</state>
        <zip>36207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saadat Ansari Internal Medicine</name>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <zip>35801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aspire Clinical Studies, LLC</name>
      <address>
        <city>Glendale</city>
        <state>Arizona</state>
        <zip>85301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southwest Clinical Research Institute</name>
      <address>
        <city>Tempe</city>
        <state>Arizona</state>
        <zip>85284</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>California Institute of Renal Research</name>
      <address>
        <city>Chula Vista</city>
        <state>California</state>
        <zip>91910</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Torrance Clinical Research</name>
      <address>
        <city>Lomita</city>
        <state>California</state>
        <zip>90717</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academic Medical Research Institute</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90022</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mohammad Ismail, Inc</name>
      <address>
        <city>Paramount</city>
        <state>California</state>
        <zip>90723</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Apex Research of Riverside</name>
      <address>
        <city>Riverside</city>
        <state>California</state>
        <zip>92505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Capital Nephrology Clinical Group</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95825</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pikes Peak Nephrology Associates</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80909</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Denver Nephrologists, PC</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nephrology and Hypertension Associates</name>
      <address>
        <city>Middlebury</city>
        <state>Connecticut</state>
        <zip>06762</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JEM Research Institute</name>
      <address>
        <city>Atlantis</city>
        <state>Florida</state>
        <zip>33462</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research of Brandon</name>
      <address>
        <city>Brandon</city>
        <state>Florida</state>
        <zip>33511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meridien Research</name>
      <address>
        <city>Brooksville</city>
        <state>Florida</state>
        <zip>34601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Riverside Clinical Research</name>
      <address>
        <city>Edgewater</city>
        <state>Florida</state>
        <zip>32123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endocrinology of Central Florida</name>
      <address>
        <city>Lake Mary</city>
        <state>Florida</state>
        <zip>32746</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meridien Research</name>
      <address>
        <city>Lakeland</city>
        <state>Florida</state>
        <zip>33805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Marcus Research Clinic</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Consulting Center</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33125</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Elite Research Institute</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33169</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prevention &amp; Strengthening Solutions, Inc</name>
      <address>
        <city>Miramar</city>
        <state>Florida</state>
        <zip>33023</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PCCC of Volusia</name>
      <address>
        <city>New Smyrna</city>
        <state>Florida</state>
        <zip>32168</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meridien Research</name>
      <address>
        <city>St. Petersburg</city>
        <state>Florida</state>
        <zip>33709</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lakeview Medical Research</name>
      <address>
        <city>Summerfield</city>
        <state>Florida</state>
        <zip>34491</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Trials of Florida</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Metabolic Research Institute</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research by Design</name>
      <address>
        <city>Evergreen Park</city>
        <state>Illinois</state>
        <zip>60805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Professional Research Network of Kansas, LLC</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington Nephrology Associates</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20814</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nephrology Center DBA, Paragon Health PC</name>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <zip>49007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Center for Clinical Trials</name>
      <address>
        <city>Biloxi</city>
        <state>Mississippi</state>
        <zip>39531</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Consultants, LLC</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>United Medical Associates</name>
      <address>
        <city>Binghamton</city>
        <state>New York</state>
        <zip>13903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Life Medi-Research and Management</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Doylestown Hospital Medical Research</name>
      <address>
        <city>Doylestown</city>
        <state>Pennsylvania</state>
        <zip>18901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Carolina Nephrology &amp; Hypertension</name>
      <address>
        <city>Orangeburg</city>
        <state>South Carolina</state>
        <zip>29118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carolina Diabetes and Kidney Center</name>
      <address>
        <city>Sumter</city>
        <state>South Carolina</state>
        <zip>29150</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southwest Houston Research, Ltd</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77099</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Advancement Center, PLLC</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southern Utah Kidney and Hypertension Center</name>
      <address>
        <city>St. George</city>
        <state>Utah</state>
        <zip>84770</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Renal Research</name>
      <address>
        <city>Gosford</city>
        <state>New South Wales</state>
        <zip>02250</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Melbourne Renal Research Group</name>
      <address>
        <city>Reservoir</city>
        <state>Victoria</state>
        <zip>03073</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 19, 2012</study_first_submitted>
  <study_first_submitted_qc>November 26, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 29, 2012</study_first_posted>
  <disposition_first_submitted>November 15, 2013</disposition_first_submitted>
  <disposition_first_submitted_qc>November 15, 2013</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">December 11, 2013</disposition_first_posted>
  <last_update_submitted>June 2, 2016</last_update_submitted>
  <last_update_submitted_qc>June 2, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 7, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperkalemia</mesh_term>
  </condition_browse>
  <pending_results>
    <submitted>October 2, 2017</submitted>
    <returned>November 2, 2017</returned>
    <submitted>March 29, 2018</submitted>
    <returned>April 30, 2018</returned>
  </pending_results>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

